Anticoagulants and their reversal

被引:136
作者
Schulman, Sam
Bijsterveld, Nick R.
机构
[1] McMaster Univ, Dept Med, Hamilton, ON, Canada
[2] Univ Amsterdam, Acad Med Ctr, Dept Cardiol, NL-1105 AZ Amsterdam, Netherlands
关键词
D O I
10.1016/j.tmrv.2006.08.002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In an exciting era with many alternatives to the old anticoagulants heparin and warfarin emerging on the scene, awareness of the possibility to reverse their effect is mandatory. In this review, the traditional antidotes for warfarin (vitamin K, plasma, and prothrombin complex concentrate) and for heparin (protamine) are described together with the newer alternatives (recombinant activated factor VII, concatameric peptides, and recombinant platelet factor 4). For some of the newer anticoagulants, possible antidotes have been identified, whereas other alternatives have been discarded. There is a very limited experience of deamino-D-arginine vasopressin or a von Willebrand factor VIII concentrate to counteract hirudin. The small direct thrombin inhibitors may be reversed with activated prothrombin complex concentrate but not with recombinant activated factor VII, whereas the latter agent appears to be effective against the pentasaccharides and the recombinant nematode anticoagulant protein C2. Additional options that may become available in the future are also discussed briefly. (c) 2007 Elsevier Inc. All rights reserved
引用
收藏
页码:37 / 48
页数:12
相关论文
共 51 条
[11]   Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial [J].
Crowther, MA ;
Julian, J ;
McCarty, D ;
Douketis, J ;
Kovacs, M ;
Biagoni, L ;
Schnurr, T ;
McGinnis, J ;
Gent, M ;
Hirsh, J ;
Ginsberg, J .
LANCET, 2000, 356 (9241) :1551-1553
[12]   Reversal of a potent investigational anticoagutant: Idraparinux with recombinant factor VIIa [J].
Dao, A ;
Tuan, B ;
Carlson, N .
AMERICAN JOURNAL OF MEDICINE, 2005, 118 (10) :1172-1173
[13]   Synthetic heparin pentasaccharide depolymerization by heparinase I: Molecular and biological implications [J].
Daud, AN ;
Ahsan, A ;
Iqbal, O ;
Walenga, JM ;
Silver, PJ ;
Ahmad, S ;
Fareed, J .
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2001, 7 (01) :58-64
[14]  
Deveras RAE, 2002, ANN INTERN MED, V137, P884, DOI 10.7326/0003-4819-137-11-200212030-00009
[15]  
Dickneite G, 1998, THROMB HAEMOSTASIS, V80, P192
[16]  
DICKNEITE G, 2006, THROMB RES 0712
[17]  
DIEHL KH, 1995, HAEMOSTASIS, V25, P182
[18]   Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin - Assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding [J].
Douketis, JD ;
Arneklev, K ;
Goldhaber, SZ ;
Spandorfer, J ;
Halperin, F ;
Horrow, J .
ARCHIVES OF INTERNAL MEDICINE, 2006, 166 (08) :853-859
[19]   Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor [J].
Elg, M ;
Carlsson, S ;
Gustafsson, D .
THROMBOSIS RESEARCH, 2001, 101 (03) :145-157
[20]   Anaphylactoid reactions to vitamin K [J].
Fiore, LD ;
Scola, MA ;
Cantillon, CE ;
Brophy, MT .
JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2001, 11 (02) :175-183